Professional Documents
Culture Documents
19857-285991-3-PB - Viii Il 10
19857-285991-3-PB - Viii Il 10
19857-285991-3-PB - Viii Il 10
Research Paper
Interleukin 10 gene rs1800896 polymorphism is associated with
the risk of prostate cancer
Hao Chen1, Jilei Tang2, Nan Shen3 and Kewei Ren4
1
Department of Urology, The First Hospital of Jiaxing, Jiaxing 314001, China
2
Department of Orthopedics, Qidong People’s Hospital, Nantong 226200, China
3
Department of Clinical Pharmacy, The Affiliated Jiangyin Hospital of Southeast University Medical School, Jiangyin 214400,
China
4
Department of Orthopedics, The Affiliated Jiangyin Hospital of Southeast University Medical School, Jiangyin 214400, China
Correspondence to: Kewei Ren, email: rkwmedicine@tom.com
Keywords: interleukin-10, polymorphism, prostate cancer, meta-analysis
Received: May 10, 2017 Accepted: June 30, 2017 Published: August 03, 2017
Copyright: Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0
(CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source
are credited.
ABSTRACT
SOC, source of controls; PB, population-based controls; HB, hospital-based controls; HWE, hardy-weinberg equilibrium;
NOS, newcastle-ottawa scale.
Ruan et al. [36] did not include three studies [22, 25, 37] for immunological monitoring, reducing the possibility of
which actually conformed to the inclusion criteria. In tumor cell survival. It may partly explain the reason why
addition, Ruan et al. extracted wrong genotype number IL-10 gene rs1800896 polymorphism was associated with
of rs1800896 polymorphism from the study conducted the decreased risk of PCa.
by Wang et al. [16]. Consequently, the reliability of The stratified analyses further confirmed this
their results [34–36] should be interpreted with caution. significant association in population-based studies and
We believe our meta-analysis has some strength over studies using the genotyping method of MassARRAY.
previous meta-analyses for the following reasons. One, In addition, stratification analysis by ethnicity indicated
we identified 16 studies including 6,301 cases and 6,510 that the G allele of rs1800896 could decrease the risk of
controls with regard to rs1800896 polymorphism and PCa among Caucasians (11 studies involving 4,438 cases
the sample size of this meta-analysis was large enough. and 3,600 controls) and increase the risk of PCa among
Two, sensitivity analysis indicated that our data about Asians (2 studies containing 360 cases and 358 controls),
rs1800896 polymorphism were trustworthy and robust. indicating different racial inheritance of Caucasians and
Recently, a study found IL-10 can completely Asians. This discrepancy may partly attribute to ethnicity-
prevent antigen-specific T cell proliferation by inhibition specific effect and sample sizes. For Caucasians, the
of the antigen-presenting capacity of monocytes through minor allele G frequency was 0.467 in this meta-analysis,
downregulation of class II major histocompatibility which was much higher than that of Asians (0.164).
complex (MHC) antigens on monocytes [38]. The finding We hypothesized that genetic heterogeneity, clinical
suggested a mechanism for tumor cells escaping from heterogeneity, different genotyping methods and random
immune surveillance. In addition, AA homozygotes errors may also be the potential reasons for different
of rs1800896 polymorphism in the IL-10 gene could findings between Asians and Caucasians. In addition,
reduce the production of IL-10 [39]. Based on these sample sizes in the subgroup of Asians were relatively
observations, we guessed that less IL-10 was beneficial small, thus the findings of Asians may be underpowered.
Figure 3: Stratification analyses of ethnicity between IL-10 rs1800896 polymorphism and PCa risk (G vs. A).
SOC, source of controls; PB, population-based controls; HB, hospital-based controls; HWE: hardy-weinberg equilibrium.
Figure 5: Begg’s tests between IL-10 rs1800896 polymorphism and PCa risk (GG vs. GA+AA).
3. Ragsdale JW 3rd, Halstater B, Martinez-Bianchi V. Prostate 16. Wang MH, Helzlsouer KJ, Smith MW, Hoffman-Bolton JA,
cancer screening. Prim Care. 2014; 41:355-370. Clipp SL, Grinberg V, De Marzo AM, Isaacs WB, Drake
CG, Shugart YY, Platz EA. Association of IL10 and other
4. Attard G, Parker C, Eeles RA, Schroder F, Tomlins SA,
immune response- and obesity-related genes with prostate
Tannock I, Drake CG, de Bono JS. Prostate cancer. Lancet.
cancer in CLUE II. Prostate. 2009; 69:874-885.
2016; 387:70-82.
17. VanCleave TT, Moore JH, Benford ML, Brock GN,
5. Xu J, Lowey J, Wiklund F, Sun J, Lindmark F, Hsu FC,
Kalbfleisch T, Baumgartner RN, Lillard JW Jr, Kittles RA,
Dimitrov L, Chang B, Turner AR, Liu W, Adami HO,
Kidd LC. Interaction among variant vascular endothelial
Suh E, Moore JH, et al. The interaction of four genes in
growth factor (VEGF) and its receptor in relation to prostate
the inflammation pathway significantly predicts prostate
cancer risk. Prostate. 2010; 70:341-352.
cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;
14:2563-2568. 18. Michaud DS, Daugherty SE, Berndt SI, Platz EA, Yeager
M, Crawford ED, Hsing A, Huang WY, Hayes RB. Genetic
6. Mocellin S, Marincola F, Rossi CR, Nitti D, Lise M. The
polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8,
multifaceted relationship between IL-10 and adaptive
and IL-10 and risk of prostate cancer. Cancer Res. 2006;
immunity: putting together the pieces of a puzzle. Cytokine
66:4525-4530.
Growth Factor Rev. 2004; 15:61-76.
19. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley
7. Fortis C, Foppoli M, Gianotti L, Galli L, Citterio
DP, Dowe A, Southgate C, Easton DF, Eeles RA, Howell
G, Consogno G, Gentilini O, Braga M. Increased
WM. Influence of cytokine gene polymorphisms on
interleukin-10 serum levels in patients with solid tumours.
the development of prostate cancer. Cancer Res. 2002;
Cancer Lett. 1996; 104:1-5.
62:3369-3372.
8. Huang S, Ullrich SE, Bar-Eli M. Regulation of tumor
20. Liu J, Song B, Bai X, Liu W, Li Z, Wang J, Zheng Y,
growth and metastasis by interleukin-10: the melanoma
Wang Z. Association of genetic polymorphisms in the
experience. J Interferon Cytokine Res. 1999; 19:697-703.
interleukin-10 promoter with risk of prostate cancer in
9. Richter G, Kruger-Krasagakes S, Hein G, Huls C, Chinese. BMC Cancer. 2010; 10:456.
Schmitt E, Diamantstein T, Blankenstein T. Interleukin 10
21. Kesarwani P, Ahirwar DK, Mandhani A, Singh AN, Dalela
transfected into Chinese hamster ovary cells prevents tumor
D, Srivastava AN, Mittal RD. IL-10 -1082 G>A: a risk for
growth and macrophage infiltration. Cancer Res. 1993;
prostate cancer but may be protective against progression of
53:4134-4137.
prostate cancer in North Indian cohort. World J Urol. 2009;
10. Filella X, Alcover J, Zarco MA, Beardo P, Molina R, 27:389-396.
Ballesta AM. Analysis of type T1 and T2 cytokines in
22. Ianni M, Porcellini E, Carbone I, Potenzoni M, Pieri AM,
patients with prostate cancer. Prostate. 2000; 44:271-274.
Pastizzaro CD, Benecchi L, Licastro F. Genetic factors
11. Yu D, Zhong Y, Li X, Li Y, Li X, Cao J, Fan H, Yuan Y, Ji Z, regulating inflammation and DNA methylation associated
Qiao B, Wen JG, Zhang M, Kvalheim G, et al. ILs-3, 6 and with prostate cancer. Prostate Cancer Prostatic Dis. 2013;
11 increase, but ILs-10 and 24 decrease stemness of human 16:56-61.
prostate cancer cells in vitro. Oncotarget. 2015; 6:42687-
23. Horvat V, Mandic S, Marczi S, Mrcela M, Galic J.
42703. doi: 10.18632/oncotarget.5883.
Association of IL-1beta and IL-10 polymorphisms with
12. Kingo K, Ratsep R, Koks S, Karelson M, Silm H, Vasar prostate cancer risk and grade of disease in Eastern Croatian
E. Influence of genetic polymorphisms on interleukin-10 population. Coll Antropol. 2015; 39:393-400.
mRNA expression and psoriasis susceptibility. J Dermatol
24. Faupel-Badger JM, Kidd LC, Albanes D, Virtamo
Sci. 2005; 37:111-113.
J, Woodson K, Tangrea JA. Association of IL-10
13. Niu WQ. The study on the association between the IL-10 polymorphisms with prostate cancer risk and grade of
promoter genetic polymorphisms and prostate cancer in disease. Cancer Causes Control. 2008; 19:119-124.
Hubei Hans population. Guo Ji Jian Yan Yi Xue Za Zhi.
2011; 32:42-43.